Contrasting Miragen Therapeutics (MGEN) & Its Rivals

Miragen Therapeutics (NASDAQ: MGEN) is one of 21 public companies in the “Medical laboratories” industry, but how does it compare to its rivals? We will compare Miragen Therapeutics to related companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for Miragen Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Miragen Therapeutics 0 1 8 0 2.89
Miragen Therapeutics Competitors 110 454 531 17 2.41

Miragen Therapeutics presently has a consensus price target of $17.19, suggesting a potential upside of 143.10%. As a group, “Medical laboratories” companies have a potential upside of 12.41%. Given Miragen Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Miragen Therapeutics is more favorable than its rivals.

Valuation and Earnings

This table compares Miragen Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Miragen Therapeutics $4.00 million -$26.51 million -5.12
Miragen Therapeutics Competitors $1.13 billion $76.65 million 216.69

Miragen Therapeutics’ rivals have higher revenue and earnings than Miragen Therapeutics. Miragen Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

19.0% of Miragen Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares Miragen Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Miragen Therapeutics -662.30% -63.57% -51.14%
Miragen Therapeutics Competitors -118.65% -181.74% -42.76%

Risk and Volatility

Miragen Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Miragen Therapeutics’ rivals have a beta of 1.24, meaning that their average stock price is 24% more volatile than the S&P 500.


Miragen Therapeutics rivals beat Miragen Therapeutics on 7 of the 13 factors compared.

Miragen Therapeutics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply